
About Collplant
Collplant is a publicly listed company based in Ness Ziona (Israel) founded in 2004. Plant-derived collagen is developed for tissue repair and 3D bioprinting. It operates in the Healthcare and Technology sectors. Collplant has raised $16.3 million across 12 funding rounds from investors including Ami Sagi, Invesco and Alpha Capital Partners. The company has 57 employees. Collplant has completed 1 acquisition, including LightSolver. Collplant offers products and services including rhCollagen, Collink.3D Bioinks, and Dermal Fillers. Its focus areas include High Tech, 3D Printing, Hardware and 3D Printing Materials. Its legal entity is CollPlant Biotechnologies Ltd.
Company details
The company was founded in 2004 in Ness Ziona, Israel, within the biotechnology sector. Plant-derived collagen and recombinant proteins are produced via a transgenic plant system for medical applications. Recombinant type I human collagen is generated for use in tissue repair, ortho-biologics, wound care, and 3D bioprinting. A dedicated 3D bioprinting division was established in 2017 to support organ and tissue fabrication.
- Headquarters Ness Ziona, Israel
- Employees 57
- Stage Public
- SectorsHealthcareTechnology
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Website collplant.com
- Social LinkedIn X Facebook YouTube
- Legal Name Collplant Biotechnologies Ltd.
- Annual Revenue$2.37 M (USD)360.39as on Dec 31, 2025
- Net Profit-$11.49 M (USD)30.83as on Dec 31, 2025
- EBITDA-$10.57 M (USD)34.8as on Dec 31, 2025
- Total Equity Funding$16.3M (USD)
in 12 rounds
- Latest Funding Round$9.25M (USD), Post-IPO
Oct 2026
- InvestorsInvesco
& 4 more
- Employee Count57
- Investments & Acquisitions
Products & Services of Collplant
Collplant offers a comprehensive portfolio of products and services, including rhCollagen, Collink.3D Bioinks, and Dermal Fillers.
Recombinant human collagen for tissue regeneration applications
Bioinks for manufacturing tissues and organs
Regenerative products for aesthetic enhancements
Funding Insights of Collplant
Collplant has successfully raised a total of $16.3M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $9.25 million completed in October 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.3M
- Total Rounds 12
- Last Round Post-IPO β $9.25M
- First Round $4.5M
(Jun 2006)
- Investors Count 5
Latest 10 of 12 funding rounds of Collplant with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2026 | $9.25M | Post-IPO | β | β | β |
| Feb 2026 | $4M | Post-IPO | β | β | β |
| Feb 2020 | $4.45M | Post-IPO | β | β | β |
| Sep 2019 | $5.5M | Post-IPO | β | β | |
| Nov 2017 | $2M | Post-IPO | β | β | |
| Oct 2017 | $5M | Post-IPO | β | β | |
| Feb 2016 | $2.07M | Post-IPO | β | β | β |
| Dec 2013 | $1.05M | Post-IPO | β | β | β |
| Apr 2008 | $8.3M | Series B | β | β | |
| Feb 2007 | $2M | Series A | β | β |
5 investors in total: 4 institutional and 1 angel.
Investors in Collplant
Collplant has secured backing from 5 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Ami Sagi, Invesco and Alpha Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A family office focused on private equity and investments. | 1984 | alphacapital.com | ||
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
Investments are directed toward Israeli technology startups by Docor. | docor.com | Tel Aviv, Israel | ||
Diversified asset management services are offered globally by Invesco. | invesco.com | Atlanta, United States | ||
AS Ami Sagi | unknown_a7a4a1908ab94b1fa |
Investor details for Collplant
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Collplant
31 people are tracked at Collplant (12 in leadership, 12 in board & advisors, 7 in team); the tracked headcount is 57.
| Name | Role | Group |
|---|---|---|
Yehiel Tal | Chief Executive Officer | Leadership |
Oded Shoseyov | CTO Director | Leadership |
Hadas Dreiher Horowitz | VP HR | Leadership |
Elana Gazal | VP Research And Development | Leadership |
Eran Rotem | Deputy CEO & Chief Financial Officer | Leadership |
Miriam Rubinchik - Stern | Head Of Research - Regenerative Breast Implant Program | Leadership |
Gal Salinas | Head Of 3dbio-printing & System Engineering | Leadership |
Philippe B. | VP Of Regulatory Affairs And Quality Assurance | Leadership |
Astrid Dafan-van Dien | Personal Assistant To CEO And Deputy Ceo, Collplant | Leadership |
Oren Fahimipoor | VP, Operations | Leadership |
Guy Ochbaum | Head Of Process Development | Leadership |
Jasmine Seror | Director Of R&d | Leadership |
Elan Penn | Board Member | Board & advisors |
Avri Havron | Board Member | Board & advisors |
Avram Hershko | Advisor | Board & advisors |
Vicki Rosen | Advisor | Board & advisors |
Joseph M. Lane | Advisor | Board & advisors |
Abhay Pandit | Advisor | Board & advisors |
Joseph Zarzewsky | Board Member | Board & advisors |
Roger J. Pomerantz | Chairman | Board & advisors |
11 more people are available in the full profile.
Complete people profiles for Collplant
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Collplant
Collplant is a publicly listed company on the NASDAQ with ticker symbol CLGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jan 2018
- Listed onNASDAQ: CLGN
- Listed entityCollPlant Biotechnologies Ltd.
- Exchange sectorHealth technology
- ISINIL0004960188
- Share price$3.91 (-2.74% on the day) · 2026-10-13
- Market capitalisation$7.4M
- EPS (diluted, trailing year)$-9.38
- Volume (last session)48,004
Financials of Collplant
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.4M | -$11.5M | -$10.6M |
| 2024 | $515,000 | -$16.6M | -$16.2M |
| 2023 | $11.0M | -$7.0M | -$6.4M |
| 2022 | $299,000 | -$16.9M | -$16.0M |
| 2021 | $15.6M | $237,000 | $838,000 |
Detailed financial statements for Collplant
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Collplant
Collplant has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include LightSolver.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Optical and quantum-inspired devices are developed for optimization solutions. | lightsolver.com | Tel Aviv, Israel | 2020 | Aug 2026 | β’β’β’β’ |
Complete acquisition details for Collplant
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Collplant
5 dated milestones of Collplant across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Collplant is founded.
- Funding First funding round of $4.5M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires LightSolver.
- Funding Latest funding round, Post-IPO, of $9.2M.
Web traffic of Collplant
The website of Collplant (collplant.com) receives about 3.2K visits a month and ranks #8,398,793 among all websites worldwide, #7,356 in Biotechnology and Pharmaceuticals.
- Monthly visits3.2K
▲ 64.3% vs previous month
- Global rank#8,398,793
among all websites
- Category rank#7,356
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.6
- Average visit23 sec
- DevicesDesktop 32% Β· Mobile 68%
Websites whose visitors overlap most with Collplant. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| collegiumpharma.com | 100% | 13.5K | #1,457,207 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Collplant
Complete news archive for Collplant
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Collplant
Collplant was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Collplant is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Collplant is a funded company, having raised a total of $16.3M across 12 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Jun 2006.
Collplant has 57 employees.
Annual revenue of Collplant is $2.37M as on Dec 31, 2025.
The company was founded in 2004 in Ness Ziona, Israel, within the biotechnology sector. Plant-derived collagen and recombinant proteins are produced via a transgenic plant system for medical applications. Recombinant type I human collagen is generated for use in tissue repair, ortho-biologics, wound care, and 3D bioprinting. A dedicated 3D bioprinting division was established in 2017 to support organ and tissue fabrication.
Collplant offers rhCollagen, Collink.3D Bioinks, and Dermal Fillers.
Yes, Collplant is publicly traded on NASDAQ under the ticker symbol CLGN.
Collplant has made 1 acquisition, including LightSolver.
Collplant has 5 investors. Key investors include Ami Sagi, Invesco, Alpha Capital Partners, Pontifax Venture Capital, and Docor.
Collplant operates through Collplant Biotechnologies Ltd..
